ImmunoGel to treat immunotherapy-resistant cancer

Year 2023
Project team Giovanni Traverso with Avik Som, Jan-Georg Rosenboom and Eric Wehrenberg
80% of cancer patients do not respond to systemic immunotherapy
Intratumoral drugs often fail
Polymeric drug delivery could overcome challenges

A personalized cancer vaccine

Systemic immunotherapy is often used to treat cancer, but 80 percent of patients do not respond to it. A new paradigm calls for injecting drugs directly into a tumor to “teach” the immune system and trigger a systemic response to widespread disease. However, current approaches for intratumoral drugs and their clinical trials often fail. This team is developing “ImmunoGel,” a polymeric drug delivery platform for intratumoral immunoadjuvants. This approach would allow controlled and extended drug release and enable clinician tracking of delivery.